Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 3:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 228 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Azithromycin Clear all
Completed Phase 3 Interventional

Roflumilast or Azithromycin to Prevent COPD Exacerbations Trial

NCT04069312
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease Severe, Chronic Bronchitis
Interventions
Roflumilast, Azithromycin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
1,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
28
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 1, 2026, 3:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pharmacokinetics and Pharmacodynamics and Selected Antibiotics During Pregnancy

NCT00214331
View directory record Official record
Conditions
Pregnancy
Interventions
ciprofloxacin, azithromycin, gentamicin
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Sep 1, 2026, 3:59 PM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 1, 2026, 3:59 PM EDT
Completed Not applicable Interventional

An Open-Label Study of the Use of Azithromycin in Patients With Symptomatic Disseminated Mycobacterium Avium-Intracellulare Complex (MAC) Infection Failing Current Therapy

NCT00002089
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Day and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Groton, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 1, 2026, 3:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Treatment of Bacterial Vaginosis

NCT00324818
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
metronidazole and azithromycin
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 1, 2026, 3:59 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease

NCT02960503
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Azithromycin, Placebo
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Sep 1, 2026, 3:59 PM EDT
Completed Phase 4 Interventional

Azithromycin in the Treatment of M. Avium Complex Lung Disease

NCT00599079
View directory record Official record
Conditions
Mycobacterium Avium Complex Lung Disease
Interventions
Azithromycin
Drug
Lead sponsor
The University of Texas Health Science Center at Tyler
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2017
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Sep 1, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

AZMATICS: AZithroMycin/Asthma Trial In Community Settings

NCT00266851
View directory record Official record
Conditions
Asthma
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
5
States / cities
Peoria, Illinois • Kansas City, Kansas • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 1, 2026, 3:59 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Azithromycin Treatment for the Airway Microbiome in Asthma

NCT03736629
View directory record Official record
Conditions
Asthma Chronic
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Sep 1, 2026, 3:59 PM EDT
Terminated Phase 2 Interventional Results available

Non-comparative Trial of the Combination of HCQ and AZI in the Treatment of ICU Patients

NCT04458948
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Azithromycin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 1, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

Targeted Therapy of Bronchiolitis Obliterans Syndrome

NCT01307462
View directory record Official record
Conditions
Bronchiolitis Obliterans
Interventions
fluticasone propionate, montelukast sodium, azithromycin
Drug
Lead sponsor
Stephanie Lee
Other
Eligibility
6 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Scottsdale, Arizona • Stanford, California • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Sep 1, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

Trial II of Lung Protection With Azithromycin in the Preterm Infant

NCT00319956
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
Hubert Ballard
Other
Eligibility
Up to 72 Hours
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 1, 2026, 3:59 PM EDT
Recruiting Phase 3 Interventional

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

NCT06082037
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Belumosudil, Azithromycin, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 1, 2026, 3:59 PM EDT
Completed Not applicable Interventional

Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Increased CD4 Cells Counts Following Anti-HIV Therapy

NCT00000883
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
51
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Sep 1, 2026, 3:59 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Early Versus Expectant Treatment of Ureaplasma Infection in Very Low Birth Weight Neonates

NCT00599053
View directory record Official record
Conditions
Bacteria Infection, Respiratory Tract Infections
Interventions
Azithromycin
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 3 Days
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Sep 1, 2026, 3:59 PM EDT
Completed Phase 4 Interventional Results available

Trial of Azithromycin vs. Doxycycline for the Treatment of Rectal Chlamydia in MSM

NCT03608774
View directory record Official record
Conditions
Anal Chlamydia Infection
Interventions
Azithromycin, Doxycycline, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years · Male only
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Sep 1, 2026, 3:59 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis

NCT00629980
View directory record Official record
Conditions
Blepharitis
Interventions
AzaSite®
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
9
States / cities
Artesia, California • Mission Hills, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Sep 1, 2026, 3:59 PM EDT
Completed Phase 2 Interventional

A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To

NCT00232154
View directory record Official record
Conditions
Sinusitis
Interventions
Zithromax™ (azithromycin) 500mg tablets, Endoscopic Sinus Surgery, Blood sampling for hematology, Blood sampling for plasma chemistry profile, Serum pregnancy test (for women of child-bearing potential)
Drug · Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
18
States / cities
Alabaster, Alabama • Birmingham, Alabama • Hoover, Alabama + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2011 · Synced Sep 1, 2026, 3:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Non-Fasting Conditions

NCT00830336
View directory record Official record
Conditions
Healthy
Interventions
Azithromycin, Zithromax®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 1, 2026, 3:59 PM EDT
Withdrawn Phase 4 Interventional

Comparison Study of Cefazolin Versus Cefazolin Plus Azithromycin Prophylaxis in Post-Cesarean Endometritis

NCT01721616
View directory record Official record
Conditions
Endometritis
Interventions
Azithromycin, Cefazolin
Drug
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Sep 1, 2026, 3:59 PM EDT
Completed Phase 4 Interventional

Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting

NCT04370782
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Azithromycin, Zinc Sulfate, Doxycycline
Drug
Lead sponsor
St. Francis Hospital, New York
Other
Eligibility
30 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Roslyn, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Sep 1, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis

NCT02024555
View directory record Official record
Conditions
Sarcoidosis; Antimycobacterial Therapy
Interventions
Levofloxacin, Ethambutol, Azithromycin, Rifampin, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Albany, New York • Cincinnati, Ohio • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 1, 2026, 3:59 PM EDT
Not yet recruiting Phase 4 Interventional

Azithromycin for Cerclage Prophylaxis

NCT07608562
View directory record Official record
Conditions
Cervical Insufficiency
Interventions
Azithromycin Prophylaxis, Azithromycin Placebo, Cefazolin, Progesterone
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Oak Lawn, Illinois • Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 1, 2026, 3:59 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II

NCT02911935
View directory record Official record
Conditions
Respiratory Syncytial Virus, Bronchiolitis
Interventions
Oral azithromycin, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Month to 18 Months
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Sep 1, 2026, 3:59 PM EDT